These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monotherapy trial design: conversion versus de novo. Kälviäinen R Epilepsy Res; 2001 May; 45(1-3):75-8; discussion 79-80. PubMed ID: 11461801 [TBL] [Abstract][Full Text] [Related]
3. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Powell G; Saunders M; Marson AG Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617 [TBL] [Abstract][Full Text] [Related]
4. Melatonin as add-on treatment for epilepsy. Brigo F; Del Felice A Cochrane Database Syst Rev; 2012 Jun; (6):CD006967. PubMed ID: 22696363 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Talati R; Scholle JM; Phung OP; Baker EL; Baker WL; Ashaye A; Kluger J; Coleman CI; White CM Pharmacotherapy; 2012 Apr; 32(4):314-22. PubMed ID: 22461121 [TBL] [Abstract][Full Text] [Related]
7. Innovative monotherapy trial designs for the assessment of antiepileptic drugs: a critical appraisal. Perucca E Eur J Clin Pharmacol; 1998 Mar; 54(1):1-5. PubMed ID: 9591922 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of drug treatment outcome in epilepsy: a clinical perspective. Perucca E Pharm World Sci; 1997 Oct; 19(5):217-22. PubMed ID: 9368921 [TBL] [Abstract][Full Text] [Related]
10. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080 [TBL] [Abstract][Full Text] [Related]
11. Lamotrigine versus carbamazepine monotherapy for epilepsy. Gamble CL; Williamson PR; Marson AG Cochrane Database Syst Rev; 2006 Jan; (1):CD001031. PubMed ID: 16437428 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and adverse effects of established and new antiepileptic drugs. Mattson RH Epilepsia; 1995; 36 Suppl 2():S13-26. PubMed ID: 8784211 [TBL] [Abstract][Full Text] [Related]
13. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Perucca E; Tomson T Epilepsy Res; 1999 Feb; 33(2-3):247-62. PubMed ID: 10094435 [TBL] [Abstract][Full Text] [Related]
14. Antiepileptic drugs' tolerability and safety--a systematic review and meta-analysis of adverse effects in dogs. Charalambous M; Shivapour SK; Brodbelt DC; Volk HA BMC Vet Res; 2016 May; 12():79. PubMed ID: 27206489 [TBL] [Abstract][Full Text] [Related]
15. Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions. Perucca E CNS Drugs; 2008; 22(11):917-38. PubMed ID: 18840033 [TBL] [Abstract][Full Text] [Related]
16. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Muller M; Marson AG; Williamson PR Cochrane Database Syst Rev; 2006 Apr; (2):CD003615. PubMed ID: 16625587 [TBL] [Abstract][Full Text] [Related]
17. Overtreatment in epilepsy: adverse consequences and mechanisms. Perucca E Epilepsy Res; 2002 Nov; 52(1):25-33. PubMed ID: 12445957 [TBL] [Abstract][Full Text] [Related]